Close Menu

NEW YORK — Cancer Genetics on Wednesday reported a nearly threefold jump in its third quarter revenues on a strong performance by its core discovery services operations.

For the three-month period ended Sept. 30, Cancer Genetics' revenues climbed to $2.1 million from $535,000 in the same period a year earlier. The revenues were generated entirely by discovery services, which includes contract research for cancer and immuno-oncology drug discovery and development.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.